Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 72.26 -0.66% -0.48
ICPT closed down 0.66 percent on Friday, May 29, 2020, on 1.16 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ICPT trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish -0.66%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Medical Specialties Diabetes Gastroenterology Hepatology Digestive Diseases Fibrosis Primary Biliary Cholangitis Bile Acid Chronic Liver Diseases Obeticholic Acid

Is ICPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 125.0
52 Week Low 47.57
Average Volume 667,586
200-Day Moving Average 83.38
50-Day Moving Average 75.19
20-Day Moving Average 83.11
10-Day Moving Average 81.79
Average True Range 5.40
ADX 21.82
+DI 24.01
-DI 31.84
Chandelier Exit (Long, 3 ATRs ) 79.77
Chandelier Exit (Short, 3 ATRs ) 85.76
Upper Bollinger Band 95.30
Lower Bollinger Band 70.93
Percent B (%b) 0.05
BandWidth 29.32
MACD Line -0.74
MACD Signal Line 1.45
MACD Histogram -2.1957
Fundamentals Value
Market Cap 1.81 Billion
Num Shares 25.1 Million
EPS -15.49
Price-to-Earnings (P/E) Ratio -4.66
Price-to-Sales 20.99
Price-to-Book 8.77
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 77.97
Resistance 3 (R3) 77.70 75.52 77.02
Resistance 2 (R2) 75.52 74.07 75.66 76.70
Resistance 1 (R1) 73.89 73.17 72.81 74.16 76.38
Pivot Point 71.72 71.72 71.17 71.85 71.72
Support 1 (S1) 70.09 70.26 69.00 70.36 68.14
Support 2 (S2) 67.91 69.37 68.05 67.82
Support 3 (S3) 66.28 67.91 67.50
Support 4 (S4) 66.55